Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

NCT00060632 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors
Lymphoma
Multiple Myeloma

Interventions

DRUG: ridaforolimus

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]